# Determining the minimum inhibitory concentrations of pyrazinamide against Mycobacterium tuberculosis clinical isolates at a neutral pH of 6.8 using the broth microdilution method

**Authors:** Maria Tamblin, Wanliang Shi, Liang Chen, Jessica Reynolds

PMC · DOI: 10.3389/fmicb.2025.1688772 · Frontiers in Microbiology · 2025-10-21

## TL;DR

Researchers developed a reliable method to test tuberculosis bacteria's resistance to pyrazinamide at a neutral pH, improving treatment accuracy.

## Contribution

A new broth microdilution method for determining pyrazinamide MICs at neutral pH, overcoming previous limitations.

## Key findings

- PZA MICs were reliably determined in M. tuberculosis isolates at neutral pH 6.8.
- MIC values ranged from ≤12.5 to 100 μg/mL across clinical isolates.
- The method is accurate, cost-effective, and suitable for resistance surveillance.

## Abstract

Pyrazinamide (PZA) is a critical component of first-line tuberculosis (TB) treatment. Misdiagnosis of PZA resistance can lead to serious consequences, highlighting the need for accurate and reliable PZA susceptibility testing. While broth microdilution is a cost-effective and widely used method for determining the minimum inhibitory concentrations (MICs) of antibiotics, its current application for PZA has been limited by the requirement for acidic conditions in conventional Mycobacterium tuberculosis culture media.

In this study, we determined the MICs of PZA against the clinical isolates of pyrazinamidase-positive M. tuberculosis at a neutral pH of 6.8 using a defined culture medium and the standard protocol of the broth microdilution method.

The results showed that PZA MICs could be reliably determined in M. tuberculosis clinical isolates, with values ranging from ≤12.5 to 100 μg/mL.

This approach overcomes the limitations of existing acidic pH-based PZA susceptibility tests and provides a reliable, accurate, cost-effective method for detecting improved PZA resistance. Implementing this method could significantly enhance TB treatment, resistance surveillance, and efforts to combat drug-resistant TB.

## Linked entities

- **Chemicals:** pyrazinamide (PubChem CID 1046)
- **Diseases:** tuberculosis (MONDO:0018076)
- **Species:** Mycobacterium tuberculosis (taxon 1773)

## Full-text entities

- **Diseases:** TB (MESH:D014376)
- **Chemicals:** PZA (MESH:D011718)
- **Species:** Mycobacterium tuberculosis (species) [taxon 1773]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12584017/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12584017/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC12584017/full.md

---
Source: https://tomesphere.com/paper/PMC12584017